Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Oct 27, 2026

Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update

The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.

Seeking Alpha • Oct 27, 2026

Quest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer's

Quest Diagnostics is upgraded to a strong buy, driven by robust earnings momentum, sector resilience, and sustained outperformance versus benchmarks. DGX delivered its fourth consecutive earnings beat, with Q3 revenue up 10% YoY and EPS up 28.7%, prompting raised full-year guidance. Quest's competitive edge is reinforced by superior margins, a strong ROE above 15%, ongoing innovation, and an investment-grade balance sheet with declining leverage.

Seeking Alpha • Oct 27, 2026

Lab testing giant Quest Diagnostics confirms patients' personal and health data was compromised during breach

Medical lab testing giant Quest Diagnostics has confirmed a cyberattack and data breach affecting an as-yet unspecified amount of sensitive patient information stored in its systems, according to a legally required disclosure with U.S. regulators.

TechCrunch • Oct 23, 2026

Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Oct 23, 2026

PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records

SAN FRANCISCO--(BUSINESS WIRE)--AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of patients of Quest Diagnostics, a New Jersey-based diagnostic testing company. Quest Diagnostics disclosed in its Securities and Exchange Commission (“SEC”) Form 8-K filing that on October 21, 2026, it identified unauthorized activity in its Quanum Lab Services Manager, a platform where certain clients can place test orders and receive or look up their resul.

Business Wire • Oct 23, 2026

Quest Diagnostics: 3 Key Takeaways for Long-Term Investors

Quest Diagnostics expects consumer health revenue growth to exceed 30% in 2026. Organic requisition volume increased 14.4% in the third quarter of 2026.

The Motley Fool • Oct 22, 2026

Why Quest's 'Good Enough' Third Quarter Wasn't Actually Enough

Quest Diagnostics did "good enough" against an "increasingly high bar," an analyst said Thursday. But Quest stock fell moderately.

Investors Business Daily • Oct 22, 2026

What Quest Diagnostics (DGX) Said on Its Q3 Earnings Call

Quest Diagnostics NYSE: DGX reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and artificial intelligence. The company raised and narrowed its full-year revenue and earnings outlook.

MarketBeat • Oct 22, 2026

Quest Diagnostics Incorporated (DGX) Q3 2026 Earnings Call Transcript

Quest Diagnostics Incorporated (DGX) Q3 2026 Earnings Call Transcript

Seeking Alpha • Oct 22, 2026